FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W184480178> ?p ?o ?g. }

• W184480178 endingPage "160" @default.
• W184480178 startingPage "152" @default.
• W184480178 abstract "Objective: To review the pharmacology, pharmacokinetics, clinical investigations, and adverse effects of sulpiride as a treatment for schizophrenia. Data Sources: Information was selected from a MEDLINE search of English-language medical literature using “sulpiride” as the search term. Manual searches of pertinent journal article bibliographies also were performed. Study Selection: Clinical investigations with a blind, controlled, randomized design and treatment durations of at least 6 weeks were preferred. Formal assessment of a patient's schizophrenia was required. One clinical investigation using a 4-week treatment duration and 1 open investigation were included for purposes of adverse reaction assessment. Data Extraction: Clinical investigations were evaluated for design, sample size, diagnosis, duration, and outcome. Data from all investigations were selected by 1 author and reviewed by both authors. Data Synthesis: Sulpiride is a substituted benzamide with selective dopaminergic blocking activity. Early pharmacology reports hypothesized that sulpiride was selective for dopamine (D) 2 receptors only, but sulpiride also blocks D 3 and D 4 receptors. Sulpiride does not block D 1 , adrenergic, cholinergic, gamma-aminobutyric acid–ergic, histaminergic, or serotonergic receptors to an appreciable extent. The oral bioavailability of sulpiride is poor, with estimates approximating 35%. Sulpiride does not appear to have an extensive first-pass metabolism, nor is it extensively protein-bound. There have been no identified active metabolites, and elimination appears to depend primarily on the kidneys. Clinical studies support sulpiride as being equally effective as active controls in the acute treatment of patients with schizophrenia. Daily doses permitted in these clinical investigations ranged from 100 to 3200 mg. Further investigation is required to determine the usefulness of sulpiride as a chronic treatment of schizophrenia and its effectiveness in treating the negative symptoms of schizophrenia. Sulpiride may cause extrapyramidal effects, autonomic effects, tardive dyskinesia, and the neuroleptic malignant syndrome. The incidence of these adverse reactions has not been established. Conclusions: Sulpiride is a safe and effective pharmacotherapeutic treatment for the acute management of schizophrenia. A unique pharmacology does not appear to provide sulpiride with a greater effectiveness than the standard antipsychotics, but may provide it with minor safety advantages." @default.
• W184480178 created "2016-06-24" @default.
• W184480178 creator A5086462893 @default.
• W184480178 creator A5090321699 @default.
• W184480178 date "1995-02-01" @default.
• W184480178 modified "2023-10-17" @default.
• W184480178 title "Sulpiride: an Antipsychotic with Selective Dopaminergic Antagonist Properties" @default.
• W184480178 cites W1568992048 @default.
• W184480178 cites W1861701908 @default.
• W184480178 cites W1963796547 @default.
• W184480178 cites W1966092598 @default.
• W184480178 cites W1973934475 @default.
• W184480178 cites W1990445980 @default.
• W184480178 cites W1991724312 @default.
• W184480178 cites W1998302082 @default.
• W184480178 cites W2010236462 @default.
• W184480178 cites W2014151243 @default.
• W184480178 cites W2014367145 @default.
• W184480178 cites W2014978199 @default.
• W184480178 cites W2017549779 @default.
• W184480178 cites W2021092126 @default.
• W184480178 cites W2021482497 @default.
• W184480178 cites W2025203404 @default.
• W184480178 cites W2026812180 @default.
• W184480178 cites W2029237088 @default.
• W184480178 cites W2032931273 @default.
• W184480178 cites W2041863334 @default.
• W184480178 cites W2043580436 @default.
• W184480178 cites W2044236179 @default.
• W184480178 cites W2048081131 @default.
• W184480178 cites W2049017069 @default.
• W184480178 cites W2058195692 @default.
• W184480178 cites W2061359205 @default.
• W184480178 cites W2064250035 @default.
• W184480178 cites W2065012733 @default.
• W184480178 cites W2065240317 @default.
• W184480178 cites W2065256090 @default.
• W184480178 cites W2066753343 @default.
• W184480178 cites W2072069319 @default.
• W184480178 cites W2077613808 @default.
• W184480178 cites W2080023028 @default.
• W184480178 cites W2080709711 @default.
• W184480178 cites W2080889861 @default.
• W184480178 cites W2081209440 @default.
• W184480178 cites W2113637843 @default.
• W184480178 cites W2119782417 @default.
• W184480178 cites W2120194850 @default.
• W184480178 cites W2334067492 @default.
• W184480178 cites W2406022298 @default.
• W184480178 cites W2887788245 @default.
• W184480178 cites W4210956182 @default.
• W184480178 cites W4253177068 @default.
• W184480178 doi "https://doi.org/10.1177/106002809502900210" @default.
• W184480178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7756714" @default.
• W184480178 hasPublicationYear "1995" @default.
• W184480178 type Work @default.
• W184480178 sameAs 184480178 @default.
• W184480178 citedByCount "234" @default.
• W184480178 countsByYear W1844801782012 @default.
• W184480178 countsByYear W1844801782014 @default.
• W184480178 countsByYear W1844801782015 @default.
• W184480178 countsByYear W1844801782016 @default.
• W184480178 countsByYear W1844801782017 @default.
• W184480178 countsByYear W1844801782019 @default.
• W184480178 countsByYear W1844801782020 @default.
• W184480178 countsByYear W1844801782021 @default.
• W184480178 countsByYear W1844801782022 @default.
• W184480178 countsByYear W1844801782023 @default.
• W184480178 crossrefType "journal-article" @default.
• W184480178 hasAuthorship W184480178A5086462893 @default.
• W184480178 hasAuthorship W184480178A5090321699 @default.
• W184480178 hasConcept C118552586 @default.
• W184480178 hasConcept C126322002 @default.
• W184480178 hasConcept C137183658 @default.
• W184480178 hasConcept C170493617 @default.
• W184480178 hasConcept C197934379 @default.
• W184480178 hasConcept C2775864247 @default.
• W184480178 hasConcept C2776412080 @default.
• W184480178 hasConcept C2780494398 @default.
• W184480178 hasConcept C2780806966 @default.
• W184480178 hasConcept C2780948584 @default.
• W184480178 hasConcept C2781353949 @default.
• W184480178 hasConcept C37000724 @default.
• W184480178 hasConcept C513476851 @default.
• W184480178 hasConcept C71924100 @default.
• W184480178 hasConcept C98274493 @default.
• W184480178 hasConceptScore W184480178C118552586 @default.
• W184480178 hasConceptScore W184480178C126322002 @default.
• W184480178 hasConceptScore W184480178C137183658 @default.
• W184480178 hasConceptScore W184480178C170493617 @default.
• W184480178 hasConceptScore W184480178C197934379 @default.
• W184480178 hasConceptScore W184480178C2775864247 @default.
• W184480178 hasConceptScore W184480178C2776412080 @default.
• W184480178 hasConceptScore W184480178C2780494398 @default.
• W184480178 hasConceptScore W184480178C2780806966 @default.
• W184480178 hasConceptScore W184480178C2780948584 @default.
• W184480178 hasConceptScore W184480178C2781353949 @default.
• W184480178 hasConceptScore W184480178C37000724 @default.

• next